Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2503-2518

  Ernst, Michael E ^a,b   Fravel, Michelle A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

allopurinol; febuxostat; gout; hyperuricemia; serum urate; xanthine oxidase inhibitor

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; AZATHIOPRINE; COLCHICINE; DESIPRAMINE; FEBUXOSTAT; HYDROCHLOROTHIAZIDE; INDOMETACIN; MAGNESIUM HYDROXIDE; MERCAPTOPURINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; THEOPHYLLINE; ULORIC; UNCLASSIFIED DRUG; URATE; WARFARIN; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; GOUT; HUMAN; HYPERURICEMIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NAUSEA; PHARMACODYNAMICS; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL;

ALLOPURINOL; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GOUT; GOUT SUPPRESSANTS; HALF-LIFE; HUMANS; HYPERURICEMIA; THIAZOLES; TISSUE DISTRIBUTION; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 74549197894     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.033     Document Type: Article

References (44)

1. Saag K.G., and Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 8 Suppl 1 (2006) S2
2. Annemans L., Spaepen E., Gaskin M., et al. Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 67 (2008) 960-966
3. Wortmann R.L. Chapter 87: Gout and hyperuricemia. In: Firestein G.S., Budd R.C., Harris Jr. E.D., et al. (Eds). Kelley's Textbook of Rheumatology. 8th ed. (2009), Saunders/ Elsevier, Philadelphia, Pa
4. Campion E.W., Glynn R.J., and DeLabry L.O. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 82 (1987) 421-426
5. Yu T.F., and Gutman A.B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 55 (1961) 179-192
6. Riedel A.A., Nelson M., Joseph-Ridge N., et al. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol. 31 (2004) 1575-1581
7. Hande K.R., Noone R.M., and Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 76 (1984) 47-56
8. Wortmann R.L. Gout and hyperuricemia. Curr Opin Rheumatol. 14 (2002) 281-286
9. Takano Y., Hase-Aoki K., Horiuchi H., et al. Selectivity of febuxostat, a novel non-purine inhibitor ofxanthine oxidase/ xanthine dehydrogenase. Life Sci. 76 (2005) 1835-1847
10. Schumacher Jr. H.R. Febuxostat: A non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs. 14 (2005) 893-903
11. Okamoto K., Eger B.T., Nishino T., et al. An extremely potent inhibitor of xanthine oxidoreductasex. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 278 (2003) 1848-1855
12. Yamamoto T., Moriwaki Y., Fujimura Y., et al. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology. 60 (2000) 34-40
13. Becker M.A., Kisicki J., Khosravan R., et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 23 (2004) 1111-1116
14. Mayer M.D., Khosravan R., Vernillet L., et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 12 (2005) 22-34
15. Khosravan R., Grabowski B., Wu J.T., et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 65 (2008) 355-363
16. Khosravan R., Kukulka M.J., Wu J.T., et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 48 (2008) 1014-1024
17. Mukoyoshi M., Nishimura S., Hoshide S., et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: Plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 38 (2008) 496-510
18. Komoriya K., Osada Y., Hasegawa M., et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 250 (1993) 455-460
19. Horiuchi H., Ota M., Kobayashi M., et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/ xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 104 (1999) 307-319
20. Osada Y., Tsuchimoto M., Fukushima H., et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 241 (1993) 183-188
21. Horiuchi H., Ota M., Kaneko H., et al. Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: Comparative studies on TEI-6720. Res Commun Mol Pathol Pharmacol. 104 (1999) 293-305
22. Hoshide S., Takahashi Y., Ishikawa T., et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 23 (2004) 1117-1118
23. Khosravan R., Grabowski B.A., Mayer M.D., et al. The effect of mild and moderate hepatic impairment on pharma- cokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 46 (2006) 88-102
24. Khosravan R., Erdman K., Vernillet L., et al. Effects of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects. Clin Pharmacol Ther. 77 (2005) 43
25. Khosravan R., Wu J.T., Joseph-Ridge N., and Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol. 46 (2006) 855-866
26. Khosravan R., Mayer M.D., Wu J.T., et al. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. ArthritisRheum 52 Suppl 9 (2005) S102-S103
27. Grabowski B.A., Khosravan R., Wu J., et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthritis Rheum. 52 Suppl 9 (2005) S103-S104
28. Khosravan R., Wu J.T., Lademacher C., et al. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 45 (2005) 1084
29. Uloric (febuxostat) [package insert] (2009), Takeda Pharmaceuticals America, Inc, Deerfield, Ill
30. Becker M.A., Schumacher Jr. H.R., Wortmann R.L., et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eightday, multicenter, phase II, randomized, double-blind, placebocontrolled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52 (2005) 916-923
31. Schumacher Jr. H.R., Becker M.A., Lloyd E., et al. Febuxostat in the treatment of gout: 5-Yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 48 (2009) 188-194
32. Kamatani N., Fujimori S.H., Hada T., et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum. 48 Suppl 9 (2003) S530
33. Kamatani N., Fujimori S., Hada T., et al. Febuxostat, a novel non-purine selective inhibitor ofxanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia. Arthritis Rheum. 50 Suppl 9 (2004) S337
34. Becker M.A., Schumacher Jr. H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 353 (2005) 2450-2461
35. Schumacher Jr. H.R., Becker M.A., Wortmann R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59 (2008) 1540-1548
36. Becker M.A., Schumacher H.R., MacDonald P.A., et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 36 (2009) 1273-1282
37. Kamatani N., Fujimori S., Hada T., et al. Febuxostat, a novel non-purine selective inhibitor of xanthine-oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia. Arthritis Rheum. 50 Suppl 9 (2004) S336-S337
38. US Food and Drug Administration (FDA), and Center for Drug Evaluation and Research (CDER). Summary Review, NDA 21-856. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_SumR.pdf Accessed June 16, 2009
39. Becker M.A., Schumacher R., Wortmann R., et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Arthritis Rheum. 50 Suppl 9 (2004) S336
40. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 20 (1977) 895-900
41. Ferraz M.B., and O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 22 (1995) 908-914
42. Chao J., and Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 11 (2009) 135-140
43. Edwards N.L. Febuxostat: A viewpoint by N. Lawrence Edwards. Drugs. 68 (2008) 1875-1876
44. Drug Topics Red Book. Update 29 (2009), Thomson Healthcare, Ann Arbor, Mich 66